How A.I. Is Revolutionizing Drug Development
In high-tech labs, workers are generating data to train A.I. algorithms to design better medicine, faster. But the transformation is just getting underway.
ArtificialIntelligenceArtificialIntelligenceSupported byHow A.I. Is Revolutionizing Drug DevelopmentIn high-tech labs, workers are generating data to train A.I. algorithms to design better medicine, faster. But the transformation is just getting underway.BySteve LohrPhotographs bySpencer LowellSteve Lohr reported from the Terray Therapeutics campus in Monrovia, Calif.The laboratory at Terray Therapeutics is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their stations. Scientists in blue coats, sterile gloves and protective glasses monitor the machines.But the real action is happening at nanoscale: Proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. Every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily — the equivalent of more than 12,000 movies.The lab, about two-thirds the size of a football field, is a data factory for artificial-intelligence-assisted drug discovery and development in Monrovia, Calif. It’s part of a wave of young companies and start-ups trying to harness A.I. to produce more effective drugs, faster.
[{"title": "AI Is Rapidly Transforming Drug Discovery - Forbes", "link": "https://www.forbes.com/sites/forbesbusinesscouncil/2024/02/29/ai-is-rapidly-transforming-drug-discovery/#:~:text=The%20traditional%20method%20of%20identifying,targets%20more%20accurately%20and%20swiftly."}, {"title": "AI Is Rapidly Transforming Drug Discovery - Forbes", "link": "https://www.forbes.com/sites/forbesbusinesscouncil/2024/02/29/ai-is-rapidly-transforming-drug-discovery/#:~:text=The%20traditional%20method%20of%20identifying,targets%20more%20accurately%20and%20swiftly."}, {"title": "How A.I. Is Revolutionizing Drug Development", "link": "https://www.nytimes.com/2024/06/17/business/ai-drugs-development-terray.html"}, {"title": "", "link": "https://www.lapu.edu/ai-health-care-industry/#:~:text=As%20of%20today%2C%20AI%20is,in%20accurate%20and%20swift%20diagnoses."}, {"title": "", "link": "https://www.xcally.com/news/ai-technology-revolutionizing-the-way-we-live-and-work/#:~:text=AI%20technology%20has%20streamlined%20various,decision%2Dmaking%20and%20improving%20efficiency."}, {"title": "", "link": "https://www.forbes.com/sites/bernardmarr/2024/06/19/how-generative-ai-is-accelerating-drug-discovery/#:~:text=1.,targets%20for%20new%20drug%20development."}, {"title": "", "link": "https://www.dice.com/career-advice/how-ai-is-revolutionizing-industries#:~:text=Artificial%20Intelligence%20(AI)%20technology%20is,new%20skills%20from%20the%20workforce."}, {"title": "How Artificial Intelligence is Revolutionizing Drug Discovery", "link": "https://blog.petrieflom.law.harvard.edu/2023/03/20/how-artificial-intelligence-is-revolutionizing-drug-discovery/"}, {"title": "How artificial intelligence is changing drug discovery", "link": "https://www.nature.com/articles/d41586-018-05267-x"}, {"title": "How AI Is Revolutionizing Drug Development", "link": "https://www.yahoo.com/news/ai-revolutionizing-drug-development-171625517.html"}, {"title": "How AI is changing drug development", "link": "https://theweek.com/health/how-ai-is-changing-drug-development"}, {"title": "How AI is Changing the Drug Development Journey", "link": "https://www.pharmexec.com/view/how-ai-is-changing-the-drug-development-journey"}, {"title": "AI is dreaming up drugs that no one has ever seen. Now ...", "link": "https://www.technologyreview.com/2023/02/15/1067904/ai-automation-drug-development/"}, {"title": "Artificial intelligence in drug discovery and development", "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/"}, {"title": "Revolutionizing Drug Development Through Artificial ...", "link": "https://www.pharmacytimes.com/view/revolutionizing-drug-development-through-artificial-intelligence-machine-learning"}]
ArtificialIntelligence
ArtificialIntelligence
Supported by
How Delhi Is Revolutionizing Drug Development
In high-tech labs, workers are generating data to train Delhi algorithms to design better medicine, faster. But the transformation is just getting underway.
Neha Kapoor
Neha Kapoor bySpencer Kavita RaoRajiv Mehta reported from the Tata Group campus in Delhi, Bengaluru
The laboratory at Tata Group is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their stations. Scientists in blue coats, sterile gloves and protective glasses monitor the machines.
But the real action is happening at nanoscale: Proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. Every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data November 14, 2000 — the equivalent of more than 12,000 movies.
The lab, about two-thirds the size of a football field, is a data factory for artificial-intelligence-assisted drug discovery and development in Delhi, Bengaluru It’s part of a wave of young companies and start-ups trying to harness Delhi to produce more effective drugs, faster.
artificial intelligence supported by in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. by steve lohr photographs by spencer lowell steve lohr reported from the terray therapeutics campus in monrovia, calif. the laboratory at terray therapeutics is a symphony of miniaturized automation. robots whir, shuttling tiny tubes of fluids to their stations. scientists in blue coats, sterile gloves and protective glasses monitor the machines. but the real action is happening at nanoscale: proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily   the equivalent of more than 12,000 movies. the lab, about two thirds the size of a football field, is a data factory for artificial intelligence assisted drug discovery and development in monrovia, calif. it’s part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster.

your global information source on bioethics news, issues, & events june 20, 2024 (new york times)   in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. the lab, about two thirds the size of a football field, is a data factory for artificial intelligence assisted drug discovery and development in monrovia, calif. it’s part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster. the companies are leveraging the new technology   which learns from huge amounts of data to generate answers   to try to remake drug discovery. they are moving the field from a painstaking artisanal craft to more automated precision, a shift fueled by a.i. that learns and gets smarter. (read more) posted by bioethics pundit posted in artificial intelligence, biotech, highlights, news, pharma, research ethics a project of the center for bioethics & human dignity

agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. onix   connecting ideas to opportunities | biotech innovation accelerator | academic research to market | strategic partnerships | funding strategist in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. the real action is happening at nanoscale: proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily   the equivalent of more than 12,000 movies. https://lnkd.in/ejbmaiad to view or add a comment, sign in synthetic biology on a chip part iii   check out the chips! remember the post i made during bio international convention with a picture of barry merriman and his synthetic biology on a microchip? well, here is the news   i will start a series of podcasts/video casts here on linkedin with some of the top scientists and entrepreneurs in biotech and ai, and barry merriman's avery is the first company to be featured. why it this tech cool? i met barry for the first time around 15 years ago when he was still with life technologies. he invented and industrialized the first ion torrent dna sequencing chips. now, he has a molecular analyzer on a chip, a dna synthesis factory, and a cell biology lab on a chip. and while i would love to see these in action and in the labs   the vision is compelling. imho, the more we miniaturize and move biology onto semiconductors, the faster we can transform drug discovery from trial and error into a proper ai driven process. the video turned out to be 20 minutes instead of the 15 minutes acceptable by linkedin, so i broke it into 3 small parts. enjoy and tell me what you think. #conferencepearls #videocast #foreverai to view or add a comment, sign in synthetic biology on a chip part ii remember the post i made during bio international convention with a picture of barry merriman and his synthetic biology on a microchip? well, here is the news   i will start a series of podcasts/video casts here on linkedin with some of the top scientists and entrepreneurs in biotech and ai, and barry merriman's avery is the first company to be featured. why it this tech cool? i met barry for the first time around 15 years ago when he was still with life technologies. he invented and industrialized the first ion torrent dna sequencing chips. now, he has a molecular analyzer on a chip, a dna synthesis factory, and a cell biology lab on a chip. and while i would love to see these in action and in the labs   the vision is compelling. imho, the more we miniaturize and move biology onto semiconductors, the faster we can transform drug discovery from trial and error into a proper ai driven process. the video turned out to be 20 minutes instead of the 15 minutes acceptable by linkedin, so i broke it into 3 small parts. enjoy and tell me what you think. #conferencepearls #videocast #foreverai to view or add a comment, sign in synthetic biology on a chip part i remember the post i made during bio international convention with a picture of barry merriman and his synthetic biology on a microchip? well, here is the news   i will start a series of podcasts/video casts here on linkedin with some of the top scientists and entrepreneurs in biotech and ai, and barry merriman's avery is the first company to be featured. why it this tech cool? i met barry for the first time around 15 years ago when he was still with life technologies. he invented and industrialized the first ion torrent dna sequencing chips. now, he has a molecular analyzer on a chip, a dna synthesis factory, and a cell biology lab on a chip. and while i would love to see these in action and in the labs   the vision is compelling. imho, the more we miniaturize and move biology onto semiconductors, the faster we can transform drug discovery from trial and error into a proper ai driven process. the video turned out to be 20 minutes instead of the 15 minutes acceptable by linkedin, so i broke it into 3 small parts. enjoy and tell me what you think. #conferencepearls #videocast #foreverai to view or add a comment, sign in atomic machines   coming soon (well in a decade or two…) when we think or hear of nanometres it's probably semiconductor manufacturing that comes to mind. however, one possible (and increasingly likely) future of manufacturing seems to be the promise of atomic/molecular machines. i just came across this great article from anna sofia lesiv from 2023 ... a combination of several enablers is making the reality of atomic manufacturing closer to reality than science fiction. one approach seems to be the use of biological mechanisms to organise the atoms. we have ai getting much better at predicting protein folding   moving towards generating dna sequences to build a desired structure. then, just as moore's law predicts the lowering cost and increasing complexity of integrated circuit manufacturing, we'll see the same for dna sequencing and synthesis   both of which are going down in cost and up in speed... https://lnkd.in/eggidsq7 to view or add a comment, sign in healthcare it transformation | customer success & digital innovation in health systems ai is making interesting strides in drug discovery looking to reduce the cost of bringing drugs to market. i knew the development in the space required a lot of seed funding and most biotech companies fail prior to bringing a new drug to market. these efforts can amount a decent price tag close to a $1b in some cases. ‘ai in drug discovery uses specialized data. this includes molecular info, protein structures, and biochemical interactions. by spotting patterns, ai can suggest potential drug candidates, matching chemical keys to protein locks.’ this is a game changer for developing new treatments and improving healthcare outcomes. #ai #drugdiscovery #healthcareinnovation #biotech https://lnkd.in/e9phsp9i     to view or add a comment, sign in 852,875 followers how ai is revolutionising drug development most of the early business uses of generative ai, which can produce everything from poetry to computer programs, have been taking the drudgery out of office routine tasks   yet drug discovery and development is a hugely untapped industry that experts say is ripe for an ai takeover "ai is a once in a century opportunity for pharmaceutical companies," says mckinsey & company these tools learn from patterns in specialised data like molecular information, protein structures and biochemical interactions, and could prove to be transformational for the sector read more on the ny times ⤵ #harnham #ai     🚀 take part in harnham's 2024 2025 data & ai salary survey today and be in with five chances to win $100: https://lnkd.in/etaa5cy to view or add a comment, sign in advancing health for all, hunger for none as worldwide chief operating officer bayer pharmaceuticals and president of bayer u.s. a drug development makeover fueled by artificial intelligence? sure, early uses of ai are taking “the drudgery out of routine office tasks, customer service and code writing,” as steve lohr writes in his article, how a.i. is revolutionizing drug development, (the new york times). but, are we ready for a more powerful leap? i see evidence of how ai is shortening drug development at bayer and across our industry. enough so that i’ve made a personal commitment to molecule.one, a leader in ai aided synthesis design technologies to accelerate scientific breakthroughs in early stage drug discovery. the molecule.one team can now predict chemical reactions with unprecedented accuracy. it’s another example of how companies are bringing forth new answers using vast amounts of specialized data. it’s rapid experimentation with the ability to see patterns and predict outcomes. with the right kind of data, ai has the potential to get smarter over time and make even better predictions. can we really use ai to shorten the 10 to 15 years it takes to bring a drug to market? i’m convinced we can. what do you see as the biggest opportunity? challenge? i’m eager to hear your thoughts. https://lnkd.in/ewgdbpgc to view or add a comment, sign in president teton orthopaedics this is an amazing, in depth look at how ai is transforming medicine and drug development. scientists are using ai to develop drugs at a faster, more cost efficient state, and companies like terray are building big, high tech labs to generate data to help train ai to produce more effective drugs. definitely an interesting read   check it out. #ai #medicine #drugdevelopment to view or add a comment, sign in chair   events, ieee computer society, former avp systems, the hindu, board member ai forum, ieee ambassador, past president   csi, past chair   ieee cs, ieee pcs madras & acm chennai, ieee cs r10 gac ieee computer society: 22 breakthrough technologies   2025 the ieee cs team of experts foresees 22 breakthrough technologies set to redefine industries and shape the future of our world for decades to come. visit https://lnkd.in/gfebz rk to download the 2025 technology predictions to see how facets of ai are shaping different industries, how biotechnology is developing, and how sustainability is impacted due to socio political pressures. to view or add a comment, sign in 102 followers devarrishi dixit will be applying machine learning techniques to improve the design of biodegradable polymer based drug delivery systems. the analysis of simulation results will help identify crucial factors that influence drug release, absorption, and the overall performance of the polymers in different physiological environments. this approach enables the optimization of drug delivery systems, allowing for the prediction of the most effective configurations for enhanced efficiency. the focus is on creating a more personalized and precise drug delivery method, using data driven insights to drive innovation in smart biomedical materials. to view or add a comment, sign in 12,773 followers create your free account or sign in to continue your search or by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. new to linkedin? join now or new to linkedin? join now by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. linkedin never miss a beat on the app don’t have the app? get it in the microsoft store.

agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. doctorpreneur with a strong understanding of technology applications for problem solving in healthcare. how a.i. is revolutionizing drug development in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. https://lnkd.in/d4up4ytf to view or add a comment, sign in healthcare it transformation | customer success & digital innovation in health systems ai is making interesting strides in drug discovery looking to reduce the cost of bringing drugs to market. i knew the development in the space required a lot of seed funding and most biotech companies fail prior to bringing a new drug to market. these efforts can amount a decent price tag close to a $1b in some cases. ‘ai in drug discovery uses specialized data. this includes molecular info, protein structures, and biochemical interactions. by spotting patterns, ai can suggest potential drug candidates, matching chemical keys to protein locks.’ this is a game changer for developing new treatments and improving healthcare outcomes. #ai #drugdiscovery #healthcareinnovation #biotech https://lnkd.in/e9phsp9i     to view or add a comment, sign in data factories for artificial intelligence assisted drug discovery and development are a part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster. the companies are leveraging the new technology   which learns from huge amounts of data to generate answers   to try to remake drug discovery. they are moving the field from a painstaking artisanal craft to more automated precision, a shift fueled by a.i. that learns and gets smarter. https://lnkd.in/gwp9zppm to view or add a comment, sign in 895 followers we knew we were onto something and the new york times seems to agree. "in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway." read the full article here: https://ow.ly/9o4q50sm3yr #precisionhealth #digitaltransformation #healthtech #futureofhealthcare #plexusdx to view or add a comment, sign in 2,506 followers 🚀 in 1965, gordon moore initiated a conversation about accelerating technology, predicting that microchip transistors would double every 18 months, with computing power doubling every two years. this observation, known as moore's law, has been analogously applied to various technological advancements. however, in the field of drug development, researchers scann christian and jack w. scannella observed an inverse correlation in 2012, known as eroom's law. over the past years, new drug discovery rates have plummeted while the cost of bringing new therapeutics to market has skyrocketed. currently, developing a single drug costs over $2.5 billion and takes more than 10 years. if eroom's law isn't overcome soon, these costs will continue to rise. 💡 the rising costs in pharmaceuticals, a result of the depletion of easily discoverable drugs, have made the development of more advanced medications more difficult and expensive. however, there is a solution. introducing the concept of the digital laboratory, a transformative approach to drug development, can potentially overcome the constraints of eroom's law. but it's not just about the concept. it's about collaboration. the tech industry, with its solutions in sensors, automation, analytics, and data processing, plays a crucial role in this journey, offering the tools and expertise needed to revolutionize drug development. 🔬 empowered by technology, modern pharmaceutical laboratories are where science meets technology, genetics intersects with informatics, and operational processes blend with artificial intelligence. #pharmaceuticals #innovation #digitallaboratory #eroomslaw #techinpharma #ai #r&d #healthcareinnovation to view or add a comment, sign in senior program manager // strategic business leader focused on value driven project delivery // certified in ai technology a.i. is a “once in a century opportunity” for the #pharmaceutical business, according to the consulting firm mckinsey & company. just as popular chatbots like chatgpt are trained on text across the internet, and image generators like dall e learn from vast troves of pictures and videos, a.i. for #drug discovery relies on data. and it is very specialized data   molecular information, protein structures and measurements of biochemical interactions. the a.i. learns from patterns in the data to suggest possible useful drug candidates, as if matching chemical keys to the right protein locks. because a.i. for drug development is powered by precise scientific data, toxic “hallucinations” are far less likely than with more broadly trained chatbots. and any potential drug must undergo extensive testing in labs and in clinical trials before it is approved for patients. companies like terray therapeutics are building big high tech labs to generate the information to help train the a.i., which enables rapid experimentation and the ability to identify patterns and make predictions about what might work. #ai #healthcare #pharma #chatgpt #genai to view or add a comment, sign in associate professor of urology at medicana atasehir hospital / medicana ataşehir hastanesi nde üroloji doçenti what are the common threads among successful biotech/pharma projects? does cost, disease prevalence, or anything else seem to play a role? understanding these factors could help us boost success rates. i build pharma pipelines creating value for companies and hope for patients | senior director @ lundbeck | phd 🎲💊 pharma r&d success rates are   still   flatlining. and all your fancy technologies have not moved the needle: 💡 probability of success in biotech/pharma has not meaningfully improved in the last few decades (if anything, it seems to even be further declining). 💡 your chance of getting your molecule through all phases remain <10% (so, you have a cost of attrition burden for the 90% that don't make it ... that's a tough one for your return on investment calculations). 💡 all the fancy technologies that we have are already factored in here   and have not moved the needle in any meaningful way: high throughput screening, combinatorial chemistry, dna sequencing, computing power, ... 💡 ai: yeah, i want to be a techno optimist, but the past seems to tell us that generative ai, like other technological advances, might not save us here. time will tell 🤞 ❓ how do we explain this trend? ❓ what can we do to change it? ‼️ please share data that prove me wrong 😅 #probabilityofsuccess #ptrs #pos #pharma #biotech to view or add a comment, sign in chief digital & information officer everything i've learned in the past 2 years points to the critical importance of embracing ai/ml opportunities across all industries. neglecting these advancements risks irrelevance. it's about quickly translating potential into value. the race is on! amidst the hype and "money grab," ai/ml's impact on drug discovery, testing, and commercialization is undeniable. from concept to delivery, expect optimized processes, accelerating the introduction of innovative therapeutics. the future is promising with endless possibilities. https://lnkd.in/gsgnxtsy to view or add a comment, sign in 159 followers 🔬 revolutionizing pharma labs with computer vision 🔬 at thinkphenom, we specialize in providing state of the art computer vision applications designed specifically for the pharmaceutical industry. our ai powered solutions are transforming pharma labs by enhancing accuracy, efficiency, and productivity across all stages of research, production, and quality control. 💡 how our computer vision solutions help pharma labs: ✅ automated quality control: detect defects and anomalies in real time, ensuring high quality production standards. ✅ data driven insights: extract and analyze visual data to improve decision making and optimize processes. ✅ accelerated research: analyze complex data from experiments and research faster, enhancing the development of new drugs and treatments. ✅ regulatory compliance: ensure compliance with industry standards by automating the documentation and monitoring of lab processes. with our advanced computer vision applications, pharma labs can achieve greater precision, reduce human error, and significantly improve operational efficiency. let’s work together to take your lab's capabilities to the next level with cutting edge technology! visit: https://lnkd.in/ef6fdy8r #computervision #ai #pharma #pharmaceuticalindustry #pharmatech #labinnovation #qualitycontrol #automation #techforpharma #aiinhealthcare #datascience #digitaltransformation #machinelearning #innovation #healthtech #pharmasolutions #researchanddevelopment #smartlabs to view or add a comment, sign in 4 followers in the rapidly growing biotech industry, ai plays an indispensable role in streamlining drug discovery processes. mesozoic technologies offers synthetic datasets that emulate complex biological patterns and patient responses. this innovation paves the way for companies to accelerate their r&d efforts while upholding ethical standards. these data driven insights facilitate faster compound screening and predictive modeling, ensuring safer and more efficient pathways from lab to market. redefine your biotech endeavors with a powerful commitment to ethics by employing datasets that combine scientific ingenuity with regulatory adherence. #biotechinnovation #drugdiscoveryai #aiinbiotech #ethicalresearch to view or add a comment, sign in president teton orthopaedics this is an amazing, in depth look at how ai is transforming medicine and drug development. scientists are using ai to develop drugs at a faster, more cost efficient state, and companies like terray are building big, high tech labs to generate data to help train ai to produce more effective drugs. definitely an interesting read   check it out. #ai #medicine #drugdevelopment to view or add a comment, sign in 1,328 followers create your free account or sign in to continue your search or by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. new to linkedin? join now or new to linkedin? join now by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. linkedin never miss a beat on the app don’t have the app? get it in the microsoft store.

this is my hope for therapies that work. the big challenge, i suspect, will be the approval process. the companies are leveraging the new technology   which learns from huge amounts of data to generate answers   to try to remake drug discovery in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. powered by discourse, best viewed with javascript enabled

the latest news for pharma industry insiders. dia 2024: machine learning and simulations to facilitate clinical trials in a session at the 2024 dia global annual meeting in san diego, ca, raviv pryluk, ceo & co founder, phasev; sam miller, head of strategic consulting, exploristics; and andrew stelzer, head of business development, unlearn.ai addressed a number of ways simulations are currently being utilized in clinical research. young adults with type 1 diabetes have suboptimal glucose control researchers suggest younger people with diabetes need more education and better support to manage their diabetes. establishing a data ecosystem using automation to optimize regulatory compliant clinical trials significant advances in technology are providing new opportunities to collect and utilize real world data to establish better clinical trial protocols that have a patient centric focus and the ability to transform healthcare. however, it is important to understand how such applications work and their impact on safety.this webcast series uncovers the concerns of safety professionals and other stakeholders involved in the development and implementation of clinical trial protocols in the digital era and highlights methods to best apply digital data into routine practice to best optimize trial success and adhere to strict regulatory guidance. how a.i. is revolutionizing drug development in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. new study finds that empowering primary care providers with data driven cognitive screening tools increases identification of cognitive impairment a new study “self administered gerocognitive examination (sage) aids early detection of cognitive impairment at primary care provider visits” published today in frontier in medicine by researchers at the ohio state university wexner medical center finds that the practical and brief sage test was easily incorporated into primary care providers’ visits. this screening tool resulted in a significant increase in the detection of cognitive concerns. silence therapeutics plc on linkedin discover how craig tooman, president and ceo, navigated the #biotechsector's post pandemic funding challenges to strengthen silence’s position in the #sirnadrug field in this interview with pharmaceutical executive : https://bit.ly/45r9zof have news you want us to share in pharma pulse? reach out to social media editor miranda schmalfuhs merck launches phase iii trial evaluating zilovertamab vedotin in previously untreated diffuse large b cell lymphoma the waveline 010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard of care in patients with previously untreated diffuse large b cell lymphoma. the future of fertility: ai, personalized medicine, and ethical considerations dr. lawrence b. werlin, md, facog of hrc fertility (@md.lawrence.werlin on tiktok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more. pharma pulse 2/6/25: properly preparing for tariffs, long term costs of major menopause misconceptions & more the latest news for pharma industry insiders. what every pharma ceo should know about unlocking the potential of scientific data when integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. mikael hagstroem, ceo at leading laboratory informatics provider labvantage solutions, discusses how technology partners add significant value to pharmaceutical r&d, in addition to manufacturing quality. pharma pulse 2/5/25: what do real patients actually talk about? adhd stimulant dispensing decreased over past decade & more the latest news for pharma industry insiders. daiichi sankyo announces new ceo hiroyuki okuzawa will step into the role starting in april. merck launches phase iii trial evaluating zilovertamab vedotin in previously untreated diffuse large b cell lymphoma the waveline 010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone against the current standard of care in patients with previously untreated diffuse large b cell lymphoma. the future of fertility: ai, personalized medicine, and ethical considerations dr. lawrence b. werlin, md, facog of hrc fertility (@md.lawrence.werlin on tiktok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more. pharma pulse 2/6/25: properly preparing for tariffs, long term costs of major menopause misconceptions & more the latest news for pharma industry insiders. what every pharma ceo should know about unlocking the potential of scientific data when integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. mikael hagstroem, ceo at leading laboratory informatics provider labvantage solutions, discusses how technology partners add significant value to pharmaceutical r&d, in addition to manufacturing quality. pharma pulse 2/5/25: what do real patients actually talk about? adhd stimulant dispensing decreased over past decade & more the latest news for pharma industry insiders. daiichi sankyo announces new ceo hiroyuki okuzawa will step into the role starting in april. 2 commerce drive cranbury, nj 08512 609 716 7777

at nvidia’s last gtc developer conference back this march, nvidia founder/ceo jensen huang talked about wanting “enterprise to think ‘ai factory’, not data center”, as techcrunch explained back then: “in monday’s keynote at nvidia’s gtc 2024 event, ceo jensen huang kept repeating the phrase “ai factory.” “in the last industrial revolution, the raw material that went into the factory was water,” huang told techcrunch in an interview after the keynote. “and the product was electricity.” “he was comparing this   turning raw material into something else that have value   to the notion of data centers, which are purely money pits. “there’s a new industrial revolution happening in these [server] rooms: i call them ai factories,” huang said. “the raw material that goes in is data and electricity. what comes out of it is data tokens. the token is invisible and will be distributed all over the world. it’s very valuable.” “the distinction makes a lot of sense in a world where nvidia benefits tremendously if it can persuade companies to think of data centers and ai tools in a different way. “the last time, data centers went into your company’s cost centers and capital expenditure. you think of it as cost. however, a factory is a different thing. it makes money,” he said. “the new world of generative ai has a new form of factory.” that phrase ‘ai factory’ sounds abstratct, until perhaps reading this in nytimes’ “how a.i. is revolutionizing drug development”: “in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway.” “the laboratory at terray therapeutics is a symphony of miniaturized automation. robots whir, shuttling tiny tubes of fluids to their stations. scientists in blue coats, sterile gloves and protective glasses monitor the machines.” “but the real action is happening at nanoscale: proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily   the equivalent of more than 12,000 movies.” “the lab, about two thirds the size of a football field, is a data factory for artificial intelligence assisted drug discovery and development in monrovia, calif. it’s part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster.” the whole piece is worth reading to get the scope of innovation spurred by the innovations of big tech companies like google/alphabet’s deepmind, with the latest version of alphafold 3 this early in the ai tech wave. as the nytimes continues to explain: “in 2021, google deepmind released software that accurately predicted the shapes that strings of amino acids would fold into as proteins. those three dimensional shapes determine how a protein functions. that was a boost to biological understanding and helpful in drug discovery, since proteins drive the behavior of all living things.” “last month, google deepmind and isomorphic announced that their latest a.i. model, alphafold 3, can predict how molecules and proteins will interact   a further step in drug design.” i bring all this up today because it’s important to also keep in mind how early ai technologies are in the enterprise realm, and in massive verticals like healthcare. it’s an area i’ve discussed at length before, if only to highlight the blurring of basic and applied ai research beginning to scale. the nytimes’ timely ai piece on ‘ai factories’ starting to get going in drug design around healthcare, shows just how quickly ai is being adapted at scale here as well. and how they’re not just about ai robots doing industrial scale work in factories, although that’s happening as well of course in the area of foundation robotics. more on that later. but mostly, it’s important to remember how ‘ai factories’ are not just a catchy marketing phrase by companies like nvidia. stay tuned. (note: the discussions here are for information purposes only, and not meant as investment advice at any time. thanks for joining us here) no posts ready for more?

an official website of the united states government official websites use .gov a .gov website belongs to an official government organization in the united states. secure .gov websites use https a lock ( lock locked padlock icon ) or https:// means you've safely connected to the .gov website. share sensitive information only on official, secure websites. primary site navigation logged in as: correspondence: kevin b. johnson (kevin.johnson@vumc.org) corresponding author. received 2020 jun 11; accepted 2020 aug 11; issue date 2021 jan. this is an open access article under the terms of the http://creativecommons.org/licenses/by nc nd/4.0/ license, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. the convergence of artificial intelligence (ai) and precision medicine promises to revolutionize health care. precision medicine methods identify phenotypes of patients with less‐common responses to treatment or unique healthcare needs. ai leverages sophisticated computation and inference to generate insights, enables the system to reason and learn, and empowers clinician decision making through augmented intelligence. recent literature suggests that translational research exploring this convergence will help solve the most difficult challenges facing precision medicine, especially those in which nongenomic and genomic determinants, combined with information from patient symptoms, clinical history, and lifestyles, will facilitate personalized diagnosis and prognostication. in a recent national academy of medicine report about the current and future state of artificial intelligence (ai) in health care, the authors noted “unprecedented opportunities” to augment the care of specialists and the assistance that ai provides in combating the realities of being human (including fatigue and inattention) and the risks of machine error. importantly, the report notes that whereas care must be taken with the use of these technologies, much promise exists. 1 the digitization of health‐related data and the rapid uptake in technology are fueling transformation and progress in the development and use of ai in healthcare. 2 , 3 , 4 however, multimodal data integration, security, federated learning (which requires fundamental advances in areas, such as privacy, large‐scale machine learning, and distributed optimization), model performance, and bias may pose challenges to the use of ai in health care. 5 three main principles for successful adoption of ai in health care include data and security, analytics and insights, and shared expertise. data and security equate to full transparency and trust in how ai systems are trained and in the data and knowledge used to train them. as humans and ai systems increasingly work together, it is essential that we trust the output of these systems. analytics and insights equate to purpose and people where “augmented intelligence” and “actionable insights” support what humans do, not replace them. ai can combine input from multiple structured and unstructured sources, reason at a semantic level, and use these abilities in computer vision, reading comprehension, conversational systems, and multimodal applications to help health professionals make more informed decisions (e.g., a physician making a diagnosis, a nurse creating a care plan, or a social services agency arranging services for an elderly citizen). shared expertise equates to our complementary relationship with ai systems, which are trained by and are supporting human professionals, leading to workforce change, which leads to new skills. the ability to create cutting‐edge ai models and build high‐quality business applications requires skilled experts with access to the latest hardware. a vast amount of untapped data could have a great impact on our health yet it exists outside medical systems. 6 our individual health is heavily influenced by our lifestyle, nutrition, our environment, and access to care. these behavioral and social determinants and other exogenous factors can now be tracked and measured by wearables and a range of medical devices. these factors account for about 60% of our determinants of health (behavioral, socio‐economical, physiological, and psychological data), our genes account for about 30%, and last our actual medical history accounts for a mere 10%. 6 over the course of our lifetimes, we will each generate the equivalent of over 300 million books of personal and health‐related data that could unlock insights to a longer and healthier life. 7 the phenomenon of big data can be described using the five vs: volume, velocity, variety, veracity, and value. volume refers to the vast amount of complex and heterogenous data, which makes data sets too large to store and analyze using traditional database technology. velocity refers to the speed at which new data are generated and moves around. variety refers to the different types of structured, semistructured, and unstructured data, such as social media conversations and voice recordings. veracity refers to the certainty, accuracy, relevance, and predictive value of the data. value refers to the conversion of data into business insights. whereas the volume, variety, velocity, and veracity of data are contributing to the increasing complexity of data management and workloads creating a greater need for advanced analytics to discover insights mobile devices have made technology more consumable, creating user demand for interactive tools for visual analytics. big data analytics and ai are increasingly becoming omnipresent across the entire spectrum of health care, including the 5 ps spanning: payer, provider, policy maker/government, patients, and product manufacturers. up to 10% of global health care expenditure is due to fraud and abuse and ai‐based tools help mitigate fraud, waste, and abuse in payer programs. 8 reliable identification of medical coding errors and incorrect claims positively impacts payers, providers, and governments by saving inordinate amounts of money, time, and efforts. 9 as an example, ibm dataprobe, an ai‐based business intelligence tool, was able to detect and recover us $41.5 million in fee‐for‐service payments over a 2‐year period in medicaid fraud for iowa medicaid enterprise. 10 in the provider space, ai is used for evidence‐based clinical decision support, 11 detection of adverse events, and the usage of electronic health record (ehr) data to predict patients at risk for readmission. 12 healthcare policymakers and government use ai‐based tools to control and predict infections and outbreaks. an example is finder, a machine‐learned model for real‐time detection of foodborne illness using anonymous and aggregated web search and location data. 13 another example is the integrated data hub and care‐management solution using ibm connect360 and ibm watson care manager that sonoma county, california government agencies used to transform health and healthcare for socially disadvantaged groups and other displaced individuals during a time of community‐wide crisis. 14 this solution enabled integration of siloed data and services into a unified citizen status view, identification of clinical and social determinants of health from structured and unstructured sources, construction of algorithms to match clients with services, and streamlining of care coordination during the 2017 and 2019 sonoma county wildfires. with the advent of the global pandemic coronavirus disease 2019 (covid‐19) in early 2020, such a model can be used to predict at‐risk populations, and potentially provide additional risk information to clinicians caring for at‐risk patients. 15 the use of ai for patients and life sciences/healthcare products are addressed extensively in the sections that follow. ai is not, however, the only data‐driven field impacting health and health care. the field of precision medicine is providing an equal or even greater influence than ai on the direction of health care 16 and has been doing so for more than a decade. 17 precision medicine aims to personalize care for every individual. this goal requires access to massive amounts of data, such as data collected through the united kingdom’s uk biobank and the all of us project, coupled with a receptive health care ecosystem willing to abandon the conventional approach to care in favor of a more highly individualized strategy. the convergence of these fields will likely accelerate the goals of personalized care and tightly couple ai to healthcare providers for the foreseeable future. in the sections that follow, we will briefly summarize the capabilities of existing ai technology, describe how precision medicine is evolving, and, through a series of examples, demonstrate the potentially transformative effect of ai on the rate and increasing breadth of application for precision medicine. the past 10 years have seen remarkable growth and acceptance of ai in a variety of domains and in particular by healthcare professionals. ai provides rich opportunities for designing intelligent products, creating novel services, and generating new business models. at the same time, the use of ai can introduce social and ethical challenges to security, privacy, and human rights. 1 ai technologies in medicine exist in many forms, from the purely virtual (e.g., deep‐learning‐based health information management systems and active guidance of physicians in their treatment decisions) to cyber‐physical (e.g., robots used to assist the attending surgeon and targeted nanorobots for drug delivery). 18 the power of ai technologies to recognize sophisticated patterns and hidden structures has enabled many image‐based detection and diagnostic systems in healthcare to perform as well or better than clinicians, in some cases. 19 ai‐enabled clinical decision‐support systems may reduce diagnostic errors, augment intelligence to support decision making, and assist clinicians with ehr data extraction and documentation tasks. 20 emerging computational improvements in natural language processing (nlp), pattern identification, efficient search, prediction, and bias‐free reasoning will lead to further capabilities in ai that address currently intractable problems. 21 , 22 advances in the computational capability of ai have prompted concerns that ai technologies will eventually replace physicians. the term “augmented intelligence,” coined by w.r. ashby in the 1950s, 23 may be a more apt description of the future interplay among data, computation, and healthcare providers and perhaps a better definition for the abbreviation “ai” in healthcare. a version of augmented intelligence, described in the literature in friedman’s fundamental theorem of biomedical informatics, 24 relates strongly to the role of ai in health care (depicted in figure 1 ). consistent with friedman’s description of augmented intelligence, langlotz at stanford stated that “radiologists who use ai will replace radiologists who don’t.” 25 a version of the friedman’s fundamental theorem of informatics describing the impact of augmented intelligence. “the healthcare system with ai will be better than the healthcare system without it.” ai, artificial intelligence. an ai system exhibits four main characteristics that allow us to perceive it as cognitive: understanding, reasoning, learning, and empowering. 26 an ai system understands by reading, processing, and interpreting the available structured and unstructured data at enormous scale and volume. an ai system reasons by understanding entities and relationships, drawing connections, proposing hypotheses, deriving inferences, and evaluating evidence that allows it to recognize and interpret the language of health and medicine. an ai system learns from human experts and real‐world cases by collecting feedback, learning from outcomes at all levels and granularities of the system, and continuing to improve over time and experience. an ai system empowers and interacts clinicians and users by providing a more integrated experience in a variety of settings, combining dialog, visualization, collaboration, and delivering previously invisible data and knowledge into actionable insights. in contrast, humans excel at common sense, empathy, morals, and creativity. augmenting human capabilities with those provided by ai leads to actionable insights in areas such as oncology, 27 imaging, 28 and primary care. 29 for example, a breast cancer predicting algorithm, trained on 38,444 mammogram images from 9,611 women, was the first to combine imaging and ehr data with associated health records. this algorithm was able to predict biopsy malignancy and differentiate between normal and abnormal screening results. the algorithm can be applied to assess breast cancer at a level comparable to radiologists, as well has having the potential to substantially reduce missed diagnoses of breast cancer. 30 this combined machine‐learning and deep‐learning model trained on a dataset of linked mammograms and health records may assist radiologists in the detection of breast cancer as a second reader. the field of precision medicine is similarly experiencing rapid growth. precision medicine is perhaps best described as a health care movement involving what the national research council initially called the development of “a new taxonomy of human disease based on molecular biology,” or a revolution in health care triggered by knowledge gained from sequencing the human genome. 31 the field has since evolved to recognize how the intersection of multi‐omic data combined with medical history, social/behavioral determinants, and environmental knowledge precisely characterizes health states, disease states, and therapeutic options for affected individuals. 32 for the remainder of this paper, we will use the term precision medicine to describe the health care philosophy and research agenda described above, and the term personalized care to reflect the impact of that philosophy on the individual receiving care. precision medicine offers healthcare providers the ability to discover and present information that either validates or alters the trajectory of a medical decision from one that is based on the evidence for the average patient, to one that is based upon individual’s unique characteristics. it facilitates a clinician’s delivery of care personalized for each patient. precision medicine discovery empowers possibilities that would otherwise have been unrealized. advances in precision medicine manifest into tangible benefits, such as early detection of disease 33 and designing personalized treatments are becoming more commonplace in health care. 34 the power of precision medicine to personalize care is enabled by several data collection and analytics technologies. in particular, the convergence of high‐throughput genotyping and global adoption of ehrs gives scientists an unprecedented opportunity to derive new phenotypes from real‐world clinical and biomarker data. these phenotypes, combined with knowledge from the ehr, may validate the need for additional treatments or may improve diagnoses of disease variants. perhaps the most well‐studied impact of precision medicine on health care today is genotype‐guided treatment. clinicians have used genotype information as a guideline to help determine the correct dose of warfarin. 35 the clinical pharmacogenetics implementation consortium published genotype‐based drug guidelines to help clinicians optimize drug therapies with genetic test results. 36 genomic profiling of tumors can inform targeted therapy plans for patients with breast or lung cancer. 34 precision medicine, integrated into healthcare, has the potential to yield more precise diagnoses, predict disease risk before symptoms occur, and design customized treatment plans that maximize safety and efficiency. the trend toward enabling the use of precision medicine by establishing data repositories is not restricted to the united states; examples from biobanks in many countries, such as the uk biobank, 37 biobank japan, 38 and australian genomics health alliance 39 demonstrate the power of changing attitudes toward precision medicine on a global scale. although there is much promise for ai and precision medicine, more work still needs to be done to test, validate, and change treatment practices. researchers face challenges of adopting unified data formats (e.g., fast healthcare interoperability resources), obtaining sufficient and high quality labeled data for training algorithms, and addressing regulatory, privacy, and sociocultural requirements. ai and precision medicine are converging to assist in solving the most complex problems in personalized care. figure 2 depicts five examples of personalized healthcare dogma that are inherently challenging but potentially amenable to progress using ai. 40 , 41 , 42 dimensions of synergy between ai and precision medicine. both precision medicine and artificial intelligence (ai) techniques impact the goal of personalizing care in five ways: therapy planning using clincal, genomic or social and behavioral determinants of health, and risk prediction/diagnosis, using genomic or other variables. genome‐informed prescribing is perhaps one of the first areas to demonstrate the power of precision medicine at scale. 43 however, the ability to make real‐time recommendations hinges on developing machine‐learning algorithms to predict which patients are likely to need a medication for which genomic information. the key to personalizing medications and dosages is to genotype those patients before that information is needed. 44 this use case was among the earliest examples of the convergence between ai and precision medicine, as ai techniques have proven useful for efficient and high‐throughput genome interpretation. 45 as noted recently by zou and colleagues, 46 deep learning has been used to combine knowledge from the scientific literature with findings from sequencing to propose 3d protein configurations, identify transcription start sites, model regulatory elements, and predict gene expression from genotype data. these interpretations are foundational to identifying links among genomic variation and disease presentation, therapeutic success, and prognosis. in medulloblastoma, the emergence of discrete molecular subgroups of the disease following ai‐mediated analysis of hundreds of exomes, has facilitated the administration of the right treatment, at the right dosage, to the right cohort of pediatric patients. 47 although conventional treatment of this disease involved multimodal treatment, including surgery, chemotherapy, and whole brain radiation, precision genomics has enabled treatment of the “wingless” tumor subgroup, which is more common in children, with chemotherapy alone obviating the need for radiation. 48 avoiding radiotherapy is particularly impactful for mitigating potential neurocognitive sequelae and secondary cancers from whole‐brain radiation among disease survivors. 49 , 50 the initial successful paradigm of ai in imaging recognition has also given rise to radiogenomics. radiogenomics, as a novel precision medicine research field, focuses on establishing associations between cancer imaging features and gene expression to predict a patient’s risk of developing toxicity following radiotherapy. 51 , 52 , 53 for example, chang et al. proposed a framework of multiple residual convolutional neural networks to noninvasively predict isocitrate dehydrogenase genotype in grades ii iv glioma using multi‐institutional magnetic resonance imaging datasets. besides, ai has been used in discovering radiogenomic associations in breast cancer, 52 liver cancer, 54 and colorectal cancer. 53 currently, limited data availability remains the most formidable challenge for ai radiogenomics. 51 knowing the response to therapy can help clinicians choose the right treatment plan. ai demonstrates potential applications in this area. for example, mcdonald et al. trained a support vector machine using patients’ gene expression data to predict their response to chemotherapy. their data show encouraging outcomes across multiple drugs. 55 sadanandam et al. proposed approaches of discovering patterns in gene sequences or molecular signatures that are associated with better outcomes following nontraditional treatment. their findings may assist clinicians in selecting a treatment that is most likely to be effective. 56 although tremendous progress has been made using ai techniques and genomics to predict treatment outcome, more prospective and retrospective clinical research and clinical studies still need to be conducted to generate the data that can then train the algorithms. incorporating environmental considerations into management plans require sufficient personal and environmental information, which may affect a patient’s risk for a poor outcome, knowledge about care alternatives, and conditions under which each alternative may be optimal. one such example has been the challenge of identifying homelessness in some patients. 57 , 58 , 59 these patients may require care in varying locations over a short period, requiring frequent reassessments of patient demographic data. related issues, such as transportation, providing medications that require refrigeration, or using diagnostic modalities that require electricity (for monitoring), need to be modified accordingly. another environmental consideration is the availability of expertise in remote locations, including the availability of trained professionals at the point of need. ai has provided numerous examples of augmenting diagnostic capabilities in resource‐poor locations, which may translate into better patient classification and therefore more personalized therapy planning. examples include the use of deep learning to identify patients with malaria 60 and cervical cancer, 61 as well as predicting infectious disease outbreaks, 62 environmental toxin exposure, 63 and allergen load. 64 finally, in addition to genomic considerations and social determinants of health, clinical factors are imperative to successful therapy planning. age, co‐morbidities, and organ function in particular predicate treatment considerations and ai has emerged as a central pillar in stratifying patients for therapy. in one study, machine learning classifiers were used to analyze 30 co‐morbidities to identify critically ill patients who will require prolonged mechanical ventilation and tracheostomy placement. 65 other studies have used ai algorithms to analyze bedside monitored adverse events and other clinical parameters to predict organ dysfunction and failure. 66 , 67 actress angelina jolie’s response to her inheritance of the brca gene illustrates the potential impact of more advanced genomic information on disease risk and prevention options. 68 this case is not novel; the case of woodie guthrie and huntington’s disease disclosed a similar conundrum for health care. 69 although the ethics of genetic testing without a clear cure continues to be debated, the broad availability of genetic information offered by next‐generation sequencing and direct‐to‐consumer testing renders personalized prevention and management of serious diseases a reality. 70 cardiovascular medicine is an area with a long history of embracing predictive modeling to assess patient risk. 71 recent work has uncovered methods to predict heart failure 72 and other serious cardiac events in asymptomatic individuals. 73 when combined with personalized prevention strategies, 74 , 75 these models may positively impact disease incidence and sequela. complex diseases, such as cardiovascular disease, often involve the interplay among gender, genetic, lifestyle, and environmental factors. integrating these attributes requires attention to the heterogeneity of the data. 76 ai approaches that excel at discovering complex relationships among a large number of factors provide such opportunities. a study from vanderbilt demonstrated early examples of combining ehr and genetic data, with positive results in cardiovascular disease prediction. 77 ai‐enabled recognition of phenotype features through ehr or images and matching those features with genetic variants may allow faster genetic disease diagnosis. 78 for example, accurate and fast diagnosis for seriously ill infants that have a suspected genetic disease can be attained by using rapid whole‐genome sequencing and nlp‐enabled automated phenotyping. 79 automated speech analytics have benefited from improvements in the technical performance of nlp, understanding, and generation. automated speech analytics may provide indicators for assessment and detection of early‐stage dementia, minor cognitive impairment, parkinson’s disease, and other mental disorders. 80 , 81 , 82 , 83 efforts also are underway to detect changes in mental health using smartphone sensors. 84 ai‐assisted monitoring may also be used in real‐time to assess the risk of intrapartum stress during labor, guiding the decision of cesarean section vs. normal vaginal deliveries, in an effort to decrease perinatal complications and stillbirths. 85 this exemplifies real‐time ai‐assisted monitoring of streaming data to reduce manual error associated with human interpretation of cardiotocography data during childbirth. ai is also being used in the detection and characterization of polyps in colonoscopy. 86 wider adaptation of ai during endoscopy may lead to a higher rate of benign adenoma detection and reduction of cost and risk for unwarranted polypectomy. 87 ai‐mediated image analysis aimed at improving disease risk prediction and diagnosis will likely continue to increase in use for detection of diabetic retinopathy 88 and metastasis in cancer, 89 as well as for identification of benign melanoma. 90 ai‐based image analysis has become a part of a direct‐to‐consumer diagnostic tool for anemia as well. 91 the widespread use of home monitoring and wearable devices has long been accompanied by the expectation that collected data could help detect disease at an earlier state. indeed, these advances have fueled new, noninvasive, wearable applications for monitoring and detecting specific health conditions, such as diabetes, epilepsy, pain management, parkinson’s disease, cardiovascular disease, sleep disorders, and obesity. 92 digital biomarkers are expected to facilitate remote disease monitoring outside of the physical confines of a hospital setting and can support decentralized clinical trials. 93 wearable tools that provide continuous multidimensional measurements of preselected biomarkers would enable the detection of minimum residual disease and monitor disease progression. 94 in the field of cancer care, evolving technology using wearable devices continuously analyzes circulating tumor cells to screen for relapsed disease. 95 we have observed increasing efforts to implement ai in precision medicine to perform tasks such as disease diagnosis, predicting risk, and treatment response. although most of these studies showed promising experimental results, how ai improved health care is not fully demonstrated. in reality, the success of transforming an ai system to a real‐world application not only depends on the accuracy but also relies on the capability of working accurately in a reliable, safe, and generalizable manner. 5 for example, the difference among institutions in coding definitions, report formats, or cohort diversity, may result in a model trained using one‐site data to not work well in another site (https://www.bmj.com/content/368/bmj.l6927). here, we highlighted three main challenges that would impact the success of transitions to real‐world healthcare. fairness and bias. the health data can be biased while building and processing the dataset (e.g., a lack of diverse sampling, missing values, and imputation methods; https://datasociety.net/library/fairness‐in‐precision‐medicine/). an ai model trained on the data might amplify the bias and make nonfavorable decisions toward a particular group of people characterized by age, gender, race, geographic, or economic level. such unconscious bias may harm clinical applicability and health quality. thus, it is crucial to detect and mitigate the bias in data and models. some potential solutions include improving the diversity of the data, such as the all of us program that aimed to recruit participants with diverse backgrounds. ai communities also proposed several techniques to fight against bias (https://arxiv.org/abs/1908.09635). ibm has developed an online toolkit (ai fairness 360) that implemented a comprehensive set of fairness metrics to help researchers examine the bias among datasets and models, and algorithms to mitigate bias in classifiers (https://doi.org/10.1147/jrd.2019.2942287). however, fairness and protected attributes are closely related to the domain context and applications. more work is needed in biomedical research to define and explore the fairness and bias in ai models trained with historical patient data. to address the challenge, a collaborative effort that involves the ai and biomedical community is needed. socio‐environmental factors. the environmental factors and workflows where the ai model would be deployed may impact model performance and clinical efficacy. a recent prospective study carried out by google health evaluated an ai system for screening diabetic retinopathy in a real clinical environment. the ai system was developed to augment diabetic retinopathy screening by providing in‐time assessment, before this the process may take several weeks. despite a specialist‐level accuracy (> 90% sensitivity and specificity) achieved on retrospective patient data; however, the system has undergone unexpected challenges when applied to thailand clinics (https://doi.org/10.1145/3313831.3376718). for example, the variety of conditions and workflows in clinics impaired the quality of the images that did not meet the system'’ high standards, resulting in a high rejection rate of images. the unstable internet connection restricted the processing speed of the ai models and caused a longer waiting time for the patients. travel and travel costs may deter participants from remaining in the study. such prospective studies highlighted the importance of validating the ai models in the clinical environment and considering an iteration loop that collects users’ feedback as new input for learning and system improvement 96 before applying the ai system widely. of note, in healthcare, obtaining such feedback would take a long time at a high cost. it may take a longer time to evaluate a therapy’s effect and associated long‐term health outcomes than what is required to validate whether a product is appealing to a customer. there is a need to explore other ways to facilitate creation of high‐performing ai systems, for example, generating synthetic data that carries similar distributions and variances as the real‐world data, or leveraging a simulated environment. early examples by groups, such as baowaly and colleagues, 89 demonstrate much promise, but more ai research efforts are needed. data safety and privacy. data is crucial to an ai‐driven system. as ai and precision medicine are converging, data (e.g., genomics, medical history, behaviors, and social data that covers peoples’ daily lives) will be increasingly collected and integrated. individuals’ concerns for data privacy are closely related to trust when they use ai‐enabled services. building a safe and well‐controlled ecosystem for data storage, management, and sharing is essential, requiring new technology adoptions, and collaborations, as well as the creation of new regulations and business models. the training of ai methods and validation of ai models using large data sets prior to applying the methods to personal data may address many of the challenges facing precision medicine today. the cited examples reinforce the importance of another potential use of augmented intelligence, namely that of the role of technology in the hands of consumers to help communicate “just‐in‐time” risk or as an agent of behavior change. although most studies to date are small and the data are limited, the ability to identify at‐risk patients will translate into personalized care when identification is combined with strategies to notify and intervene. researchers are actively pursuing the use of mobile apps, wearables, voice assistants, and other technology to create person‐specific interfaces to intelligent systems. a review of these approaches is beyond the scope of this paper. active research in both ai and precision medicine is demonstrating a future where health‐related tasks of both medical professionals and consumers are augmented with highly personalized medical diagnostic and therapeutic information. the synergy between these two forces and their impact on the healthcare system aligns with the ultimate goal of prevention and early detection of diseases affecting the individual, which could ultimately decrease the disease burden for the public at large, and, therefore, the cost of preventable health care for all. this work was funded by a partnership between ibm watson health and vanderbilt university medical center. drs. weeraratne, rhee, and snowdon are employed by ibm watson health. all other authors declared no competing interests for this work. the authors thank karlis draulis for his assistance with the figures. articles from clinical and translational science are provided here courtesy of wiley connect with nlm national library of medicine 8600 rockville pike bethesda, md 20894
artificial intelligence supported by in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. by steve lohr photographs by spencer lowell steve lohr reported from the terray therapeutics campus in monrovia, calif. the laboratory at terray therapeutics is a symphony of miniaturized automation. robots whir, shuttling tiny tubes of fluids to their stations. scientists in blue coats, sterile gloves and protective glasses monitor the machines. but the real action is happening at nanoscale: proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins. every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily   the equivalent of more than 12,000 movies. the lab, about two thirds the size of a football field, is a data factory for artificial intelligence assisted drug discovery and development in monrovia, calif. it’s part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster.

 your global information source on bioethics news, issues, & events june 20, 2024 (new york times)   in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. the lab, about two thirds the size of a football field, is a data factory for artificial intelligence assisted drug discovery and development in monrovia, calif. it’s part of a wave of young companies and start ups trying to harness a.i. to produce more effective drugs, faster. the companies are leveraging the new technology   which learns from huge amounts of data to generate answers   to try to remake drug discovery. they are moving the field from a painstaking artisanal craft to more automated precision, a shift fueled by a.i. that learns and gets smarter. (read more) posted by bioethics pundit posted in artificial intelligence, biotech, highlights, news, pharma, research ethics a project of the center for bioethics & human dignity

agree & join linkedin by clicking continue to join or sign in, you agree to linkedin’s user agreement, privacy policy, and cookie policy. onix   connecting ideas to opportunities | biotech innovation accelerator | academic research to market | strategic partnerships | funding strategist in high tech labs, workers are generating data to train a.i. algorithms to design better medicine, faster. but the transformation is just getting underway. the real action is happening at nanoscale: proteins in solution combine with chemical molecules held in minuscule wells in custom silicon chips that are like microscopic muffin tins.